Acute Leukemias

A collection of features and news articles published in ASH Clinical News related to acute leukemias.

HHS Allows Novartis to Pay Travel Expenses for Tisagenlecleucel Patients

The U.S. Department of Health and Human Services (HHS) will allow Novartis to cover travel, lodging, and meal expenses for Medicaid and Medicare beneficiaries...

Decitabine Maintenance May Improve Survival in Older Patients With AML

One year of maintenance therapy with brief monthly courses of intravenous decitabine was associated with improved overall survival (OS) among older patients with acute...

Study Finds Higher Rates of Leukemia in 9/11 Responders and Recovery Workers

Investigators  discovered an increase in the incidence of leukemia in first responders and other recovery workers who were at the World Trade Center (WTC)...

Early Intensification of Intrathecal Chemotherapy Reduces Risk of Relapse in Pediatric ALL

Two additional doses of intrathecal therapy early during induction treatment for children with newly diagnosed acute lymphocytic leukemia (ALL) who were at increased risk...
WIB_icon

Achievement of MRD Negativity Predicts Favorable Prognosis in RUNX1-RUNX1T1+ AML

In patients with acute myeloid leukemia (AML) with t(8;21)(q22;q22.1)/RUNX1-RUNX1T1+ fusion, serial assessment of measurable residual disease (MRD) can identify people at a high risk...

Updates on ASH Clinical Practice Guidelines in Development

In 2019, the American Society of Hematology (ASH) continued its efforts to develop and publish evidence-based clinical practice guidelines to help practicing hematologists and...

Are Clinical Trial Exclusion Criteria for Patients With AML Too Strict?

Watch our interview with Abby Statler, MD, MPH. In a study presented at the 2019 ASH Annual Meeting, researchers found that certain comorbidities in patients...

QUAZAR: Oral Azacitidine Maintenance Improves Survival in Transplant-Ineligible AML

According to research presented as a late-breaking abstract at the 2019 ASH Annual Meeting, treatment with CC-486, an oral formulation of the hypomethylating agent...

Is Blinatumomab a New Standard of Care for Young Patients With B-Cell ALL?

Compared with standard chemotherapy, blinatumomab as consolidation prior to hematopoietic cell transplantation (HCT) is associated with fewer severe toxicities, higher response rates, and longer...

MRD Response Predicts Survival in Blinatumomab-Treated Patients With Relapsed/Refractory ALL

In patients with relapsed/refractory B-cell precursor acute lymphocytic leukemia (ALL) who are treated with blinatumomab, achieving minimal residual disease (MRD) was associated with improved...